• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Prostate Cancer Drug Pathway Analyzer 2015

  • ID: 2673688
  • January 2015
  • Region: Global
  • Bioseeker

Extra value: One year of free online updates included with this product

There are today at least 413 targeted molecular therapies known to affect more than 249 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 280 drug targets that are included in this drug-pathway analyzing tool. No less than 274 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer.

Pathway Coverage
- BioCarta# 249 Pathways
- KEGG# 193 Pathways
- NCI-Nature# 244 Pathways
- NetPath# 32 Pathways

Pipeline Coverage
Marketed# 30
Pre-registration# 2
Phase III# 19
Phase II# 152
Phase I# 80
Preclinical# 119
No Data# 4
Suspended# 5
Ceased# 224

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Johnson & Johnson Services, Inc. Sanofi S.A. Astellas Pharma, Inc. Teva Pharmaceutical Industries Ltd. Astrazeneca PLC Emergent BioSolutions, Inc.